A combination GIP and GLP-1 receptor could be the next groundbreaking treatment option for people with overweight or obesity, researchers reported. The first-of-its-kind class of combination drug was approved by the U.S. Food and Drug Administration (FDA) in May 2022 for the treatment of type 2 diabetes (T2D), but a new study suggests that it … Continue reading A New Era of Obesity Treatment